The success of this strategy was first validated by FDA approval of Avastin, a humanized VEGF-neutralizing monoclonal antibody for metastatic colorectal cancer in combination with standard care 34 and subsequently for the treatment of non-small-cell lung cancer and metastatic breast cancer 35, 36. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.